Showing results (41-50 of 75) with videos related to

Sort By:
Pageof 8
Leukemia|March 24, 2021
Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerationsRoland B Walter, Yishai Ofran, Agnieszka Wierzbowska, et al.
Annals of Hematology|August 23, 2016
Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocolMoshe Mittelman, Kalman Filanovsky, Yishai Ofran, et al.
Leukemia Research|July 1, 2022
Re-induction versus salvage for D14-resiudal acute myeloid leukemia: A retrospective multi-center studyAvraham Frisch, Shlomzion Aumann, Tsila Zuckerman, et al.
Annals of Hematology|June 22, 2022
Venetoclax in combination with FLAG-IDA-based protocol for patients with acute myeloid leukemia: a real-world analysisOfir Wolach, Avraham Frisch, Liat Shargian, et al.
Annals of Hematology|September 13, 2019
Midostaurin in combination with intensive chemotherapy is safe and associated with improved remission rates and higher transplantation rates in first remission-a multi-center historical control studyTamar Berger, Uri Rozovski, Yakir Moshe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 18, 2010
Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopesYishai Ofran, Haesook T Kim, Vladimir Brusic, et al.
American Journal of Hematology|August 1, 2012
Allogeneic stem cell transplantation for patients with chronic myeloid leukemia: risk stratified approach with a long-term follow-upTsila Zuckerman, Tamar Katz, Nuhad Haddad, et al.
Annals of Hematology|June 23, 2022
Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysisShai Shimony, Jonathan Canaani, Eitan Kugler, et al.
European Journal of Haematology|September 19, 2020
Midostaurin in combination with chemotherapy is most effective in patients with acute myeloid leukemia presenting with high FLT3-ITD allelic ratio who proceed to allogeneic stem cell transplantation while in first complete remissionYishai Ofran, Ronit Leiba, Avraham Frisch, et al.
American Journal of Hematology|April 9, 2021
Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practiceArie Apel, Yakir Moshe, Yishai Ofran, et al.
Pageof 8